Comparison · NCT02362672-528d4581
NKTR-181 vs Placebo: Patient Global Impression of Change (PGIC): Number of Responders
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NKTR-181 vs Placebo: Patient Global Impression of Change (PGIC): Number of Responders. Trial comparisons, record NCT02362672-528d4581. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02362672-528d4581
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.515 | 0.459 | 0.57 | wilson | |
| Risk in group 2 | 0.332 | 0.281 | 0.387 | wilson | |
| Risk difference, group 1 minus group 2 | 0.182 | 0.104 | 0.257 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.55 | 1.28 | 1.88 | log | |
| Odds ratio, group 1 over group 2 | 2.13 | 1.54 | 2.96 | log | |
| Number needed to treat, for one more participant with the outcome on NKTR-181 than on Placebo | 5.48 | 3.89 | 9.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NKTR-181 | NKTR-181 (Double-blind treatment phase) | 159 | 309 | OG000 |
| Group 2 | Placebo | Placebo (Double-blind treatment phase) | 100 | 301 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Patient Global Impression of Change (PGIC): Number of Responders
- Description
The PGIC assesses the change in overall status relative to the initiation of the treatment. The scale measures global change of overall status on a 7-point scale (1 = No change (or condition has got worse), 2 = Almost the same, 3 = A little better, 4 = Somewhat better, 5 = Moderately better, 6 = Better, 7 = A great deal better). The proportion of subjects responding A great deal better and better was summarized by treatment group.
- Time frame
- Screening Baseline through Week 12
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain
- NCT number
- NCT02362672
- Phases
- PHASE3
- Conditions
- Low Back Pain, Chronic Pain
- Interventions
- NKTR-181 BID tablets, Placebo to match NKTR-181 BID tablets
- Lead sponsor
- Nektar Therapeutics
- Results first posted
- 2020-09-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02362672?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02362672-528d4581